Pharmacogenetics of Oxaliplatin as Adjuvant Treatment in Colon Carcinoma

ERCC1 and ERCC2 Polymorphisms Predict Clinical Outcomes of Oxaliplatin-Based Chemotherapies in Gastric and Colorectal Cancer: A Systemic Review and Meta-analysis

(2011) Ming Yin et al.   CLINICAL CANCER RESEARCH

Gender Influences Treatment and Survival in Colorectal Cancer Surgery

(2011) E Carter Paulson et al.   DISEASES OF THE COLON & RECTUM

Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin

(2010) Michael A Gordon et al.   PHARMACOGENOMICS

Large age and hospital-dependent variation in administration of adjuvant chemotherapy for stage III colon cancer in southern Netherlands

(2009) L. N. van Steenbergen et al.   ANNALS OF ONCOLOGY

Gender Disparities in Metastatic Colorectal Cancer Survival

(2009) A. Hendifar et al.   CLINICAL CANCER RESEARCH

Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes

(2009) Penelope A. Bradbury et al.   Pharmacogenetics and Genomics

ERCC22251A>C genetic polymorphism was highly correlated with early relapse in high-risk stage II and stage III colorectal cancer patients: A preliminary study

(2008) Ming-Yii Huang et al.   BMC CANCER

Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy

(2008) L Paré et al.   BRITISH JOURNAL OF CANCER

Platinum Resistance: The Role of DNA Repair Pathways

(2008) L. P. Martin et al.   CLINICAL CANCER RESEARCH

Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients

(2008) Dina M. Kweekel et al.   EUROPEAN JOURNAL OF CANCER